Trial Profile
A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study Evaluating the Safety and Efficacy of Baricitinib in Combination With Topical Corticosteroids in Adult Patients With Moderate-to-Severe Atopic Dermatitis Who Have Experienced Failure to Cyclosporine or Are Intolerant to, or Have Contraindication to, Cyclosporine
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 13 Sep 2023
Price :
$35
*
At a glance
- Drugs Baricitinib (Primary) ; Corticosteroid; Hydrocortisone; Triamcinolone
- Indications Atopic dermatitis
- Focus Registrational; Therapeutic Use
- Acronyms BREEZE-AD4
- Sponsors Eli Lilly and Company
- 24 Jul 2023 The trial has been completed in Netherlands, according to European Clinical Trials Database record.
- 20 May 2023 Status changed from active, no longer recruiting to completed.
- 30 Mar 2023 The trial has been completed in Austria, according to European Clinical Trials Database record.